toxicity, lower than expected efficacy, and off-target effects (Miele, Spinelli et al. 2012 ).
In particular, the tumor microenvironment can present a formidable barrier that hinders the transport of drug molecules as well as nano-sized vehicles (Primeau, Rendon et al. 2005 , Hait and Hambley 2009 , Warren 2013 . In order to be effective, nanoparticle-mediated drug delivery needs to utilize the vascular network to preferentially reach the tumor site and penetrate into the cancerous tissue to establish cytotoxic concentrations, avoid uptake by the reticulo-endothelial system (RES), diffuse through the extra-cellular matrix (ECM) mesh of proteins, remain close or be uptaken by the cancer cells, and efficiently release the payload of drug molecules to achieve cytotoxicity. To address these requirements and increase the efficacy of chemotherapy, nanoparticles can be functionalized with various compounds to help reduce systemic distribution and avoid intrinsic cellular resistance mechanisms (Koziara, Whisman et al. 2006 , Bertrand, Wu et al. 2014 ). Yet uncoordinated angiogenic stimuli by proliferating and hypoxic cancer cells induce a heterogeneous vascular response, characterized by tortuous vessels with abnormal structure 2 and irregular flow (Izuishi, Kato et al. 2000, Minchinton and Tannock 2006) . The inadequacy of the vascular network promotes intra-tumoral tissue regions with heterogeneous proliferative, hypoxic, and apoptotic states, while severely impairing the transport of and the response to systematically-administered drugs and nanoparticles.
The efficacy of nanoparticles in cancer treatment is typically evaluated with in vitro and in vivo experimental models, which are indispensable for pre-clinical evaluation.
However, in vitro models lack key features of cancerous tissue found in vivo, including a vascular network, while in vivo models present challenges due to systemic interactions which may not be necessarily easily teased apart. As a complement to these experimental venues, computational simulation of cancer nanotherapy has aimed to provide the capability for system-level analysis (Frieboes, Sinek et al. 2006 , Decuzzi, Pasqualini et al. 2009 , Godin, Driessen et al. 2010 , Li, Al-Jamal et al. 2010 , Li and Reineke 2011 , Li, Panagi et al. 2012 , van de Ven, Wu et al. 2012 , Gao, Li et al. 2013 , Kaddi, Phan et al. 2013 , Li, Czyszczon et al. 2013 , van de Ven, Abdollahi et al. 2013 , Wu, Frieboes et al. 2014 ). In particular, we have recently studied via mathematical modeling the extravasation, uptake, and distribution of nanoparticles subject to heterogeneous tumor tissue and vascular conditions (Curtis, England et al. 2016 , Curtis, Rychahou et al. 2016 , Reichel, Curtis et al. 2017 ).
The distribution and penetration of 2-and 3-layered gold nanoparticles were recently evaluated in vitro (England, Priest et al. 2013) and in vivo . The purpose of these nanoparticles was to increase chemotherapy efficacy , England, Gobin et al. 2015 via enhanced distribution and penetration into tumor tissue.
The 3-layer gold nanoparticles were functionalized with phosphatidylcholine, 3 hexadecanethiol and high-density lipoprotein (England, Priest et al. 2013 ). Computational modeling was implemented (Curtis, England et al. 2016) to simulate the performance of these nanoparticles in vivo given measurements in vitro, with the goal to begin bridging the gap from the pre-clinical to the clinical setting. The model parameters were set from experimental measurements with 2D and 3D cultures of A549, H358, and PC9 Non-Small
Cell Lung Cancer (NSCLC) cells (England, Priest et al. 2013 .
In this study, computational simulation is employed to evaluate the role of vascular density-induced heterogeneity on the distribution of 3-layered gold nanoparticles in tumor tissue and the associated drug release. Small metastatic lesions are simulated in a well vascularized organ, such as the lung, and cisplatin is used as the model drug. The nanoparticle effectiveness is analyzed by calculating fractions of control for tumors of various blood vessel densities after bolus administration of the drug loaded nanoparticles.
Tumor therapy is simulated with various drug inhibitory concentrations calibrated to achieve a 50% reduction in tumor size (IC50) at four timepoints (24hr, 48hr, 72hr, 96hr) post treatment initiation. This work represents a first step towards quantifying tumor response to drug-loaded nanoparticles based on vascular-network induced tissue heterogeneity.
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MATERIALS AND METHODS
Nanoparticle Synthesis and Characterization
Three-layered nanoparticles were previously created in (England, Priest et al. 2013 ). Briefly, citrate-stabilized gold nanoparticles were synthesized by reducing chloroauric acid with trisodium citrate (Frens 1973) . The first layer applied was 1-Hexadecanethiol (TL), followed by phosphatidylcholine (PC), and then HDL.
Nanoparticles were characterized via extinction spectra using ultraviolet-visible (UV-Vis) spectrometry, zeta potential measurements, DLS (dynamic light scattering) to determine hydrodynamic size (intensity distribution) in solution, determination of shape and size with scanning electron microscopy, and confirmation of presence of lipids on the particle cores using a Fourier transform infrared (FTIR) instrument. Cisplatin (7.5 mg) was then added to the nanoparticles in solution and allowed to react for 2 h (England, Priest et al. 2013) .
Experimental Cytotoxicity Data
As described in (England, Priest et al. 2013 ), A-549 cells were maintained in standard culture conditions, and used to form tumor spheroids. Cytotoxicity was first measured in 3D cell culture with free drug at varying concentrations (1024, 256, 64, 16, 4, 1, 0.25, 0 .0625 µM) for 48 h. The spheroids were exposed to varying concentrations of drug-loaded nanoparticles calculated by considering two parameters: (1) the loading efficiency from HPLC data showing the exact concentration of drug encapsulated onto the nanoparticles and (2) the percent of drug released over the 48-hour period.
Computational Modeling
Tumor Growth
The tumor growth component is based on (Macklin, McDougall et al. 2009 , Wu, Frieboes et al. 2013 where μ is cell-mobility, P is oncotic pressure, χE is haptotaxis, and E is the density of the extracellular matrix (ECM). Refer to (Macklin, McDougall et al. 2009 ) for a more detailed description of E and χE. The overall tumor growth can be associated with the rate of volume change by assuming that the cell density within the proliferating region remains constant:
where is the non-dimensionalized net proliferation rate (described below).
Angiogenesis
The angiogenesis component is based on (McDougall, Anderson et al. 2006) to represent blood flow, vascular leakage and vascular network remodeling resulting from wall shear stress and mechanical stress imposed by the tumor tissue as it changes in time.
Briefly, as the tumor grows within a vascularized environment, the tissue has access to oxygen and nutrients diffusing from the vasculature. The interstitial flow of oxygen and nutrients is influenced by tissue pressure and by distance from the nearest vessel. Refer to (Macklin, McDougall et al. 2009 , Wu, Frieboes et al. 2013 ) for a more detailed description of the angiogenesis model. Under steady-state conditions, the formulation of oxygen and nutrient uptake and decay is (Macklin, McDougall et al. 2009 , van de Ven, Wu et al. 2012 , Wu, Frieboes et al. 2014 :
where x is position, t is time, 1vessel is the characteristic function for the vasculature (equals 1 at vessel locations and 0 otherwise), pi is interstitial pressure, and h is the hematocrit in the vascular network [48] . Extravasation is modulated by the extravascular interstitial 
where diffusion of particles into the tumor tissue is modulated by the interstitial pressure (van de Ven, Wu et al. 2012 ). Particle extravasation is assumed to be
, where Wu et al. 2012) . The extravasation of particles is concentration dependent, simulating first order kinetics. The decay constant α is measured from previous in vivo experiments, in which the particle half-life is estimated to be 12 hours (England, Huang et al. 2015) . The diffusivity of the particles was calibrated from the combination of charge and size properties based on measurements obtained in vitro (England, Priest et al. 2013 ).
Transport of drug
Drug G is released at the point of extravasated particles and diffuses through the tumor tissue with the coefficient DG. The rate G decay  combines the effects of drug uptake by tumor and normal cells and the wash-out from the interstitial space, and reflects the half-life of the drug (Curtis, England et al. 2016 ):
The drug release G release  from the particles is represented by (Curtis, England et al. 2016) :
C is the release of drug which is fitted in time to follow the results obtained from in vitro experiments in [38] . The drug release rate thus combines the effect of particle concentration and drug release profile. All diffusion equations have the boundary condition 0
where B is the diffusible substance.
Drug effect on tumor 9
Cisplatin is a cell cycle dependent drug, and thus its cytotoxic effect is only exerted on proliferating cells. Drug effect is included into the proliferation term where is the rate of drug-induced cell death (Wu, Frieboes et al. 2014 
where λA is the apoptosis rate, λM is the mitosis rate, and GN is the non-dimensional rate of volume loss in the necrotic tumor core (it is assumed that cellular debris is constantly degraded and the fluid is removed (Wu, Frieboes et al. 2014) ). This pharmacodynamic model assumes that cell proliferation and apoptosis rates are similar before and after drug therapy. Cell death is assumed to be instantaneous.
Calibration of Rate of Drug-Induced Cell Death
The model parameters for oxygen, drug effect and tumor growth were calibrated using data obtained experimentally with NSCLC tumor spheroids to find an 48hr IC50 for simulated avascular spheroids (in vitro simulations) (England, Priest et al. 2013) . A detailed description of the in vitro experiments used to calibrate the simulations can be found in (Curtis, England et al. 2016) , which includes the synthesis, functionalization, characterization, drug loading, and drug release of the nanoparticles and cytotoxicity experiments in 2D and 3D cell culture. Since the concentration of NP's and drug were not changed among the four IC50's, the free drug concentration after 48 h of exposure was calculated based on the data from our previous study (Curtis, England et al. 2016) . Then, the 24hr, 72hr, and 96hr IC50 avascular treatment drug concentrations were scaled by the p  effect  same proportion as the change in drug effect. The trapezoid method was used to calculate the corresponding AUC's to quantify the avascular IC50's.
Tumor Tissue Heterogeneity
The values for drug-induced cell death used for the avascular IC50's were employed in therapy simulations with vascularized lesions (simulations of in vivo condition). To link the differences in drug effect to the effects of heterogeneous vascularization density, the in vivo simulations used the same nanoparticle concentration in a bolus dose as was needed in the in vitro simulations to achieve the IC50. All tumors grown in host tissue with the same pre-existing vessel densities but different oxygen thresholds for hypoxia and necrosis were grown to the same initial radius of 0.56mm. In vivo simulations were run for a sufficient amount of time to obtain the smallest tumor radii following NP bolus injection and were used to compare the efficacy of cisplatin-loaded nanoparticles among the various cases. The tumor blood vessel density was calculated by dividing vessel surface area (vessel length x vessel cross sectional area) by the tumor area.
The main tumor, nanoparticle, and drug parameters and their values are summarized in Table 1 .
Parameter Value Reference
Tumor proliferation rate 1 day -1 Measured in (Curtis, England et al. 2016) Oxygen diffusivity 1 (*) (Wu, Frieboes et al. 2013) Oxygen transfer rate from vasculature 5 (*) (Wu, Frieboes et al. 2013) Oxygen uptake rate by proliferating tumor cells 1.5 (*) (Wu, Frieboes et al. 2013) Oxygen uptake rate by hypoxic tumor cells 1.3 (*) (Wu, Frieboes et al. 2013) Oxygen uptake rate by tumor microenvironment 0.12 (*) (Wu, Frieboes et al. 2013) Oxygen decay rate 0.35 (*) (Wu, Frieboes et al. 2013) NP extravasation from angiogenic vs. (Wu, Frieboes et al. 2013 ). (*) Value is rescaled by the square of the simulation system characteristic length (1 cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen diffusivity (Nugent and Jain 1984) (1 x 10 -5 cm 2 s -1 ).
CDDP: cisplatin; NP: 3-layered gold nanoparticles characterized in (England, Priest et al. 2013 , Curtis, England et al. 2016 ).
Four levels of tissue heterogeneity were obtained, respectively labeled "very low," "low," "medium," and "high," by varying the angiogenesis-induced tissue vascularization based on the response to tumor angiogenic factors (TAF) that were in proportion to the tumor tissue hypoxic and necrotic levels. The values for these levels are defined in Table   2 . The hypoxic threshold defines the oxygen level at which tissue becomes hypoxic (quiescent but still viable) and ceases to proliferate, while the necrotic thresholds defines the oxygen level at which the tissue becomes necrotic (dead). 
Level of Tissue Heterogeneity Tumor hypoxic threshold
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RESULTS
Experimental data
The 3-layer gold nanoparticles were previously characterized as having a maximum wavelength of 5.35 nm, a hydrodynamic diameter of 80.2 ± 12.4 nm, and a zeta potential of -6 mV (Curtis, England et al. 2016 ). The cisplatin loading efficiency was 78.9 ± 0.7% (Curtis, England et al. 2016 ). The nanoparticles released 59.1 ± 2.0% of drug within the first 3 hours, 76.7 ± 1.84 within 48 h, and 78.9 ± 2.1) by 96 h .
Simulation of heterogeneous tumor growth
Tumors were first grown under the conditions of VERY LOW, LOW, MEDIUM and HIGH heterogeneity as defined in Table 2 to the same radius (0.566 mm) before treatment. The simulated tumors during the initial growth phase are shown in Figure 1 .
Depending on the level of heterogeneity, this growth took varying amounts of time, with the HIGH case taking the longest (22.7 simulated days). The tissue heterogeneity is characterized in Figure 2 as a function of the tumor radius. While the intra-tumoral vessel density initially increased for the VERY LOW and LOW cases, it plateaued for radii beyond 0.40 mm (Figure 2A) . In contrast, the density for MEDIUM and HIGH conditions decreased for radii below 0.31 and 0.28 μm, respectively, before becoming larger. The proliferative tissue fraction corresponding to these vascular densities indicates that for a 15 radius of 0. 566 mm right before start of treatment, these fractions were being maintained at 96, 82, 68, and 55% for VERY LOW, LOW, MEDIUM and HIGH conditions, respectively ( Figure 2B ). At this radius, the hypoxic tissue fractions were correspondingly lower, at 2.4, 4.8, 10.0, and 20.2% (Figure 2C) , while the necrotic fraction values were 1.2, 12.6, 21.9, and 25.3%, respectively. Compared to the more stable values maintained for the proliferating and hypoxic as the tumor radius increased, the necrotic fractions 
Calibration of drug effect
A simulated tumor growing in the dish in vitro, surrounded by plentiful oxygen and nutrients, is shown in Figure 3A . This tumor was exposed after 30 d to drug in silico for 48 h to determine the value for the drug effect to achieve a 50% reduction in tumor size (the "IC50") ( Figure 3B) . This value was then assigned the units of the drug concentration to achieve the same regression with the tumor spheroids in the experiments in vitro (Curtis, England et al. 2016) . A range of area-under-the-curve values were obtained, as shown in Table 3 . increases from VERY LOW to HIGH, the penetration and spatial distribution of nanoparticles and the drug released from them correspondingly becomes more heterogeneous. The deepest nanoparticle penetration is achieved with the VERY LOW case, for which the drug release is concentrated in the inner core of the tumor. In contrast, in the HIGH case the nanoparticles become stuck in the tumor periphery, unable to penetrate into the tissue. This is consistent with previous modeling work showing that tumor tissue heterogeneity leads to inhomogeneous small molecular and nanoparticle distribution, with the highest concentrations occurring on the periphery (Frieboes, Wu et al. 2013 , Curtis, Wu et al. 2015 . Interestingly, although in the LOW case the nanoparticles penetrate deeper, their concentration is more heterogeneously distributed than in the MEDIUM case, suggesting that the relationship between heterogeneity and nanoparticle penetration is not linear (Frieboes, Wu et al. 2013 , Curtis, Wu et al. 2015 . The drug release from the nanoparticles within the first 4 h for the various drug strengths is shown in Figure 6 . Consistently, the highest concentrations were achieved for HIGH tissue heterogeneity and the lowest for the VERY LOW heterogeneity. The 24 h IC50 strength exhibited the greatest differential between the various levels of heterogeneity, at 7 μM for HIGH and 5 μM for VERY LOW, in contrast to the 96 h IC50, which evinced 1 μM for HIGH and 0.75 μM for VERY LOW.
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23 Figure 6 . Drug release from the nanoparticles within the first 4 h for the various drug strengths.
The area-under-the-curve (AUC) for the nanoparticles within tumor tissue is shown in Figure 7A . Whereas the AUC for the 24 h IC50 condition declined from the VERY LOW to the HIGH heterogeneity levels, ranging from 7 to 6 %initial.h, the other three IC50
conditions had the highest values for the LOW level. At this level, the 72 h IC50 predominated overall at 17.5 %initial.h. In contrast, the highest AUC at the VERY LOW case was attained for the 48 h IC50 at 14 %initial.hr, while the highest values for the MEDIUM and HIGH conditions were for the 96 h IC50, at 15 and 13.8 %initial.h, respectively. In spite of these inhomogeneous outcomes for the nanoparticles, the intratumoral vascular AUC for the drug released from them had a more consistent pattern 24 across the levels of heterogeneity and drug strength ( Figure 7B) . The 24 h IC50 evinced the highest values overall, increasing from 9.6 μM.h to 13.1 μM.h for the VERY LOW and HIGH levels, respectively. The values for the other drug strengths followed the same trend but at lower values, ranging for the VERY LOW to HIGH levels at 3.5, 2.1, and 1.5 μM.h to 4.7, 2.8, and 2.0 μM.h for 48, 72, and 96 h IC50 strengths, respectively. Thus, the 96 h IC50 had the lowest drug AUC values. On the other hand, the 96 h IC50 drug strength was equally ineffective across all levels of heterogeneity, achieving at best a 9% reduction in tumor radius. This information is summarized in Figure 10 , highlighting the nonlinear decrease in tumor radii for the 25 different drug strengths across the four levels of heterogeneity. While higher drug strengths, as represented by lower IC50 values, yielded higher response, the magnitude of this response was dependent on the level of tissue heterogeneity. 
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DISCUSSION
This study builds upon previous experimental (England, Priest et al. 2013 and modeling work (Curtis, England et al. 2016) to evaluate the effect of vascular density-driven tissue heterogeneity on NSCLC tumor response to cisplatin delivered via 3-layered gold nanoparticles. As such, this work represents a first step towards the development of a principled approach to predict nanotherapy efficacy using patient-tumorspecific characteristics, such as proliferative index and vascular density. Tumors with different intra-tumoral vascular densities (Figure 1) were first simulated by varying the oxygen thresholds for hypoxia and necrosis to yield different proportions of proliferating, hypoxic and necrotic tissue (Figure 2) . Next, using experimentally-obtained data with 3-layered gold nanoparticles loaded with cisplatin (England, Priest et al. 2013 , the magnitude of the drug effect in silico was calibrated for inhibitory drug concentrations to achieve 50% tumor tissue remission over 24, 48, 72, and 96 h ( Figures   5, 6 ). The resulting inhomogeneous intratumoral nanoparticle and drug AUC values (Figure 7 ) yield correspondingly heterogeneous tumor regressions (Figures 8, Figure 10) .
This system was then used to determine the expected tumor size based on the fraction of viable tumor tissue and intratumoral vascular density (Figure 9) .
The results show that vascular tumor density coupled with the drug strength non-trivially influences the nanoparticle uptake and washout, and the associated tissue response. The 28 drug strength affects the proportion of proliferating, hypoxic and necrotic tissue fractions, which in turn dynamically affect and are affected by the vascular density. A higher drug strength may be able to achieve a stronger tumor regression but only if the intra-tumoral vascular density is beyond a certain threshold ( Figure 9B ). In contrast, drug strengths of lower magnitude may yield similar responses regardless of vascular density. Although regression generally correlated with drug strength, the level of vascular density-driven tissue heterogeneity is shown to modulate this regression, to the point that the difference in drug strength may not matter (Figure 10 ). Since drug strength is a key clinical parameter underlying both response and systemic toxicity, the overall results support the notion that drug strength remains a critical modeling parameter for predictive evaluation. This is consistent with recent modeling work that combined an optimization approach to determine optimal nanoparticle sizes for maximum tumor regression (Chamseddine, Frieboes et al. 2018 ).
This study establishes a first step towards a more systematic methodology to assess the effect of tumor tissue vascular density on the response to nanotherapy. With experimentally-measurable parameter values, the system could be expanded to evaluate other types of nanoparticles and drugs. Vascular permeability and blood volume could be quantified by positron emission tomography (Chen, Tong et al. 2017) . In particular for nonsmall cell lung cancer (NSCLC), tumor parameters such as vascular density could be measured via imaging or histological analysis (Ma, Ren et al. 2016) . Additionally, there exist numerous methods for detecting tumor hypoxia, including the detection of hypoxiainduced proteins through the HIF transcription factor (Zhong, De Marzo et al. 1999, Brahimi-Horn and Pouyssegur 2005) . The concept of manipulating the vascular density to achieve improved response (e.g., "vascular normalization" (Jain 2001) ), as has been tried 29 for NSCLC with small molecule tyrosine kinase inhibitors or monoclonal antibodies that target VEGF (Hall, Le et al. 2015) , may find further utility depending on the drug strength.
Clinically, angiogenesis inhibitors have been shown to lead to improvements in overall survival when combined with standard first line and second line therapy (Hall, Le et al. 2015) . In cases where tumor vascular density is determined by the model to be inadequate for a desired level of response, angiogenesis inhibitors may be able to change this density to augment the nanotherapy efficacy.
The interaction between vasculature, cells, nanoparticles, and drug molecules is a complex kinetic process in need of further consideration not only in experimental work but also in future computational modeling and simulation studies. Recently, a vascularized tumor model system was proposed that considers the differences in drug kinetics among various cellular compartments (Curtis, van Berkel et al. 2018) . Further studies could combine drug kinetics with a nanoparticle delivery model. The model used herein simulates cell death as an instantaneous process. However, cell cycle dependent drugs such as cisplatin rely on apoptosis and may take several hours before cytotoxic effects are realized (Siddik 2003) . Thus, another consideration for future work is to account for the delay in the drug cytotoxic action. Additionally, there are several well characterized drug resistance mechanisms such as decreased intracellular transport, enzymatic deactivation, and alteration in proteins involved in apoptotic pathways (Stewart 2007) .These mechanisms could be integrated to create more comprehensive pharmacodynamics models.
